Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
Titel:
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
Auteur:
Bellmunt, J. González-Larriba, J.L. Prior, C. Maroto, P. Carles, J. Castellano, D. Mellado, B. Gallardo, E. Perez-Gracia, J.L. Aguilar, G. Villanueva, X. Albanell, J. Calvo, A.